CD180 Overexpression in Follicular Lymphoma

Civil Hospices of Lyon

Status: Completed

Conditions: Follicular Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT02978898

69HCL16_0564

Details and patient eligibility

About

Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD.

Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.

Enrollment: 184 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Samples from patients with:

  • LF: Follicular lymphoma
  • MCL: Mantle cell lymphoma
  • CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia
  • MZL : splenic marginal zone
  • Clt :control B-cells

Exclusion criteria

• Patient <18 years old

Trial design

184 participants in 2 patient groups

LN Lymph nodes

Description:

Samples obtained from patients with : LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells

PB peripheral blood

Description:

Samples obtained from patients with : LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells